New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
07:03 EDTBDSIBioDelivery Sciences completes enrollment for Phase 3 trial of Clonidine
BioDelivery Sciences has completed enrollment of all patients required for its initial Phase 3 study of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. The trial is a multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with PDN. This is the first of two pivotal trials that would be required for submission of a New Drug Application to the FDA. FDA has granted Fast Track designation for the program.
News For BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 26, 2014
09:30 EDTBDSIBioDelivery Sciences management to meet with Summer Street
Subscribe for More Information
September 17, 2014
08:44 EDTBDSIBioDelivery Sciences remains takeout candidate for Endo, says Summer Street
Summer Street believes a potential takeover of BioDelivery Sciences (BDSI) by partner Endo (ENDP) is no less likely after Endo made a bid to acquire Auxilium (AUXL). The firm believes an Endo buyout of BioDelivery is likely a 2015 event when BioDelivery's Bunavail for opioid dependence is on the market and BEMA Buprenorphine is facing FDA approval. Summer Street says it is a buyer of BioDelivery Sciences on weakness this morning and keeps a Buy rating on the name with a $28 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use